Invivyd (NASDAQ:IVVD) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note released on Tuesday, Benzinga reports. The firm currently has a $15.00 target price on the stock.

Invivyd Stock Down 3.8 %

NASDAQ IVVD opened at $0.85 on Tuesday. The stock has a market cap of $101.44 million, a PE ratio of -0.45 and a beta of 0.66. Invivyd has a fifty-two week low of $0.84 and a fifty-two week high of $5.20. The business has a 50 day moving average price of $1.12 and a two-hundred day moving average price of $2.28.

Hedge Funds Weigh In On Invivyd

Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new position in Invivyd in the 1st quarter worth approximately $56,000. Tidal Investments LLC purchased a new position in shares of Invivyd during the 1st quarter valued at approximately $126,000. XTX Topco Ltd boosted its stake in shares of Invivyd by 68.1% during the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after buying an additional 15,376 shares during the last quarter. Chase Investment Counsel Corp purchased a new position in shares of Invivyd during the 1st quarter valued at approximately $271,000. Finally, Cornercap Investment Counsel Inc. purchased a new position in shares of Invivyd during the 2nd quarter valued at approximately $86,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.